Every 10-Q that GREATER CANNABIS CO (GCAN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow GCAN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GCAN filings page.
Trafalgar International, Inc. (GCAN) reported no revenue for the three and six months ended June 30, 2026, continuing its pre‑revenue status. Operating expenses fell sharply, leading to an operating loss of $11,555 for the quarter and $44,931 for the first half of 2026.
Net income was driven entirely by non‑operating items. The company recorded a $621,450 gain on cancellation of debt and a $1,483 gain on cancellation of preferred stock A, producing quarterly net income of $611,378 and first‑half net income of $578,002, compared with losses in 2025. Cash was only $111 at June 30, 2026, with current liabilities of $12,239 and negative working capital of $12,128, and management concluded there is substantial doubt about its ability to continue as a going concern through June 2027.
During the period, all related‑party loans and third‑party notes payable were eliminated, materially reducing liabilities and stockholders’ deficiency to $(12,128). A 1‑for‑1,500 reverse stock split became effective in October 2025, and 994,379 common shares were outstanding as of August 14, 2026. On June 29, 2026, control shifted to Trafalgar Asset Management, LLC, which now holds approximately 96.62% of voting power via Series A and super‑voting Series B preferred stock, and the company is transitioning from cannabis‑focused activities toward broader financial services, technology and intellectual property businesses.
The Greater Cannabis Company, Inc. reports unaudited results for the quarter ended March 31, 2026, with no revenue and a net loss of $33,376. Operating expenses fell to $33,376 from $43,536 a year earlier, mainly from lower stock-based and other operating costs.
Cash was only $1,439 against current liabilities of $776,464, resulting in a stockholders’ deficit of $775,025. Management explicitly concludes there is substantial doubt about the company’s ability to continue as a going concern through March 2027 without new funding.
The company continues to pursue development of a cannabinoid therapeutic licensed from Shaare Zedek Scientific Ltd., with Phase II clinical work dependent on securing specialized API and additional capital. A 1-for-1,500 reverse stock split and creation of super-voting Series B preferred shares have centralized voting control while leaving 944,935 common shares outstanding as of May 6, 2026.
The Greater Cannabis Company (GCAN) filed its Q3 2025 report. The company generated $0 revenue and reported a net loss of $36,099 for the quarter. For the nine months ended September 30, 2025, net loss was $669,369.
As of September 30, 2025, cash was $21,355 against $1,129,697 in current liabilities, resulting in a stockholders’ deficit of $(1,108,342). Management disclosed substantial doubt about the company’s ability to continue as a going concern.
The company completed a 1-for-1,500 reverse stock split in October 2025; shares outstanding were 900,256 as of September 30, 2025, and 944,935 as of October 22, 2025. During 2025, the FirstFire note accrued $306,323 in default penalties and interest; an amendment provides the note is deemed satisfied upon completion of the reverse split. On October 22, 2025, GCAN created Series B Convertible Preferred (1,000 shares), issuing it to the CEO in exchange for $20,000 of waived compensation; these shares carry 51.0% voting power.